Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Imagion Biosystems Ltd. ( (AU:IBX) ) is now available.
Imagion Biosystems Limited has notified the ASX of the cessation of a class of options, with 353,474 IBXAAR options expiring on March 23, 2026, without being exercised or converted. The expiry of these options slightly reduces the company’s pool of potential equity dilution but does not affect its current issued capital, representing a routine capital management event rather than a change in operating strategy or market focus.
The most recent analyst rating on (AU:IBX) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
More about Imagion Biosystems Ltd.
Imagion Biosystems Limited, listed on the ASX under the code IBX, operates in the biotechnology and medical technology sector. The company focuses on developing diagnostic and imaging solutions, leveraging advanced biosensing and imaging technologies aimed at improving disease detection and monitoring in clinical and research settings.
Average Trading Volume: 2,348,109
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.3M
For a thorough assessment of IBX stock, go to TipRanks’ Stock Analysis page.